Most of the UK media are covering the publication of new NICE guidelines on familial breast cancer. One recommendation, that has been widely reported, is that women with a high risk of familial breast cancer should be given preventative drug treatment…
The National Institute of Health and Care Excellence (NICE) has today released updated guidelines on the care of women who are at increased risk of breast cancer due to their family history. One of the main changes to the original guidance from 2004 is that NICE now recommends drug treatment with tamoxifen or raloxifene to reduce risk of breast cancer in a specific group of women who are at high risk of breast cancer and have not had the disease.
They say that these treatments could help prevent breast cancer in about 488,000 women aged 35 years and older.
The updated guideline has also made changes to the recommended level of risk at which relatives of a woman with familial breast cancer can be offered genetic testing, and to the screening offered to specific groups of women.
Breast cancer is referred to as “familial” when there are an unusually high number of cases of breast, ovarian or related cancers in a family – more than would be expected by chance alone.
This may be an indication that faulty genes have caused or contributed to the development of the cancer. Three of the genes that are known to be involved in causing familial breast cancer are BRCA1, BRCA2 and TP53.
Read more about the genetics of breast cancer
In cases where breast cancer runs in a family, doctors can estimate a woman’s risk of breast cancer based on:
The NICE guideline lays out how doctors should carry out this assessment and estimate a woman’s risk. It recommends that women who have not had breast cancer who meet the following criteria should be offered referral to secondary care by their GP:
If the woman has relatives with breast cancer but does not meet these criteria, if her family history includes any of the following the GP should seek advice from secondary care:
Women with mutations in BRCA1, BRCA2 or TP53 should be referred directly to a specialist genetics clinic (see below for more information on genetic testing).
The NICE guideline also gives detailed family history criteria that suggest that a woman should be offered referral to a specialist genetics clinic for further assessment and potentially genetic counselling and genetic testing. Women should be offered referral if their risk assessment finds that they have:
The NICE guideline gives recommendations to doctors on exactly which computer programs and methods can be used to calculate a woman’s breast cancer risk.
Women whose lifetime risk from age 20 is estimated to be more than 17% but less than 30% are considered to be at moderate risk, and those at 30% or greater risk are considered to be at high risk. Women whose risk between the ages of 40 and 50 is estimated to be 3-8% are considered to be moderate risk and those at more than 8% risk are considered to be high risk.
NICE’s guideline gives detailed recommendations on exactly what kind of surveillance should or should not be offered to women with familial breast cancer for early detection of breast cancer. This is based on their specific levels of risk, age and genetic make-up.
The changes in the updated guidance include:
As in their previous guidance, NICE recommends that genetic testing for a family should first be carried out on an affected family member if possible, to try and identify whether they carry a mutation in genes such as BRCA1, BRCA2 or TP53.
However, if an affected relative is not available, NICE’s new recommendation is that genetic testing can be offered to relatives of people affected by familial breast cancer if their combined risk of carrying a mutation in BRCA1 or BRCA2 is 10% or more. Previously this was recommended only if their combined risk was 20% or more. Genetic testing can also be offered to individuals with breast or ovarian cancer if their combined BRCA1 and BRCA2 mutation carrier probability is 10% or more.
The main change reported on in the news is that NICE now recommends offering the drugs tamoxifen or raloxifene to specific groups of women at risk of familial breast cancer to reduce their chances of getting the disease.
NICE recommends that:
Yes. Like all drug treatments both tamoxifen and raloxifene can cause side effects.
The most common side effects of tamoxifen are menopausal-type symptoms, such as:
Common side effects of raloxifene include:
As well as risk assessment, surveillance and preventive drug treatment, the guideline does discuss risk reducing surgery such as bilateral mastectomy (removal of both breasts) and breast reconstruction surgery.
This is the type of surgery that the actress Angelina Jolie announced she had undergone after genetic testing showed that she was at high risk of developing breast cancer. The NICE guideline notes that bilateral mastectomy is appropriate only for a small proportion of women who are from high-risk families.
The guideline also includes recommendations on less radical approaches to risk reduction in women with a family history of breast cancer. This includes informing women about factors that could increase their risk of breast cancer, such as taking the oral contraceptive pill in women aged over 35, taking hormone replacement therapy, drinking alcohol, or being overweight.
NICE also recommends that women with a family history of breast cancer:
Further details of these recommendations are available in the full guideline that can be accessed online at the NICE website